Findings from all three studies highlight the significant benefits of HFX™ for PDN¹ in the clinical and real-world settings.  HFX for PDN is the only spinal cord stimulation (SCS) system approved by the U.S. Food and Drug Administration with a specific on-label indication for treating PDN.